Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2019

View Archived Issues

Gold nanoparticles found to improve CRISPR delivery system for gene editing

DGM1 as a novel biomarker of response to enzastaurin in DLBCL and glioblastoma

ROCK inhibition suppresses tumorigenesis in resistant CSCs

Phase I/IIa trial of gB/pp65 CMV immunotherapeutic vaccine in recurrent glioblastoma

FDA approves sBLA for Botox for pediatric patients with upper limb spasticity

'Cheap and straightforward' structure predictions

Results presented from first-in-human study of REGN-3767 against advanced malignancies

Data reported from phase II study of pembrolizumab for recurrent respiratory papillomatosis

First-in-human results demonstrate [64Cu]/[67Cu] to be a nearly ideal theranostic pair

Early clinical results reported from trials of anti-CD32b antagonistic antibody BI-1206

RSLV-132 moves into phase III for Sjogren syndrome after reduced fatigue seen in phase II

X-Cutag Therapeutics patents new compounds for cancer

Lin Bioscience synthesizes tubulin polymerization inhibitors

Epizyme discloses new KAT inhibitors

Applied Therapeutics initiates phase I/II study of AT-007 in galactosemia

Dextenza approved by FDA to treat ocular inflammation following ophthalmic surgery

FDA approves Vyleesi for hypoactive sexual desire disorder in premenopausal women

Symdeko obtains FDA approval for cystic fibrosis in children aged 6-11 years

Talzenna approved in E.U. for germline BRCA-mutated locally advanced or metastatic breast cancer

Kissei Pharmaceutical identifies new CGRP antagonists

Bayer initiates phase III trial of aflibercept in retinopathy of prematurity

Oscotec describes new LRRK2 inhibitors

Axsome enrolls first patient in phase III GEMINI study of AXS-05 for MDD

FDA allows Athenex's IND to study pegtomarginase for advanced malignancies

FDA lifts partial clinical hold on phase III CANOVA trial of venetoclax in multiple myeloma

FDA clears Minerva's IND for huMNC2-CAR44 for metastatic breast cancer

FDA issues complete response letter for quizartinib in relapsed/refractory FLT3-ITD AML